2021
Longitudinal Changes in Neuromelanin MRI Signal in Parkinson's Disease: A Progression Marker
Gaurav R, Yahia‐Cherif L, Pyatigorskaya N, Mangone G, Biondetti E, Valabrègue R, Ewenczyk C, Hutchison R, Cedarbaum J, Corvol J, Vidailhet M, Lehéricy S. Longitudinal Changes in Neuromelanin MRI Signal in Parkinson's Disease: A Progression Marker. Movement Disorders 2021, 36: 1592-1602. PMID: 33751655, PMCID: PMC8359265, DOI: 10.1002/mds.28531.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkersCase-Control StudiesFemaleHumansMagnetic Resonance ImagingMaleMelaninsParkinson DiseaseProspective StudiesSubstantia NigraConceptsTotal intracranial volumePD patientsHealthy volunteersParkinson's diseaseIntracranial volumeObservational case-control studySubstantia nigra pars compactaDirect noninvasive assessmentDisease-modifying treatmentsEarly PD patientsFemale PD patientsTherapeutic drug trialsCase-control studyNeuromelanin-sensitive MRI techniquesNeuromelanin-sensitive imagingMale patientsFemale patientsPars compactaCohort IICohort IDrug trialsPatientsImaging biomarkersNoninvasive assessmentDisease severity
2020
Low cerebrospinal fluid volume and the risk for post-lumbar puncture headaches
Droby A, Omer N, Gurevich T, Kestenbaum M, Mina Y, Cedarbaum JM, Aizenstein O, Giladi N, Mirelman A, Thaler A. Low cerebrospinal fluid volume and the risk for post-lumbar puncture headaches. Journal Of The Neurological Sciences 2020, 417: 117059. PMID: 32739500, DOI: 10.1016/j.jns.2020.117059.Peer-Reviewed Original ResearchMeSH KeywordsCerebrospinal FluidHumansMagnetic Resonance ImagingNervous System DiseasesPilot ProjectsPost-Dural Puncture HeadacheSpinal PunctureConceptsPost-LP headachePost-lumbar puncture headacheLow CSF volumeT1-weighted imagesCerebrospinal fluidCSF volumePuncture headacheDisease-modifying clinical trialsLow cerebrospinal fluid (CSF) volumePatient-related factorsGradient-echo T1-weighted imagesCerebrospinal fluid volumeLP headacheAdverse eventsMedical workupClinical trialsBrain MRINeurological conditionsHeadacheMRI scansT MR scannerWhite matterCSF collectionGray matterPilot study
2011
A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease
Salloway S, Sperling R, Keren R, Porsteinsson AP, van Dyck CH, Tariot PN, Gilman S, Arnold D, Abushakra S, Hernandez C, Crans G, Liang E, Quinn G, Bairu M, Pastrak A, Cedarbaum JM. A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease. Neurology 2011, 77: 1253-1262. PMID: 21917766, PMCID: PMC3179648, DOI: 10.1212/wnl.0b013e3182309fa5.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAgedAged, 80 and overAlzheimer DiseaseAmyloid beta-PeptidesApolipoprotein E4Dose-Response Relationship, DrugDouble-Blind MethodFemaleFollow-Up StudiesHumansInositolMagnetic Resonance ImagingMaleMental Status ScheduleMiddle AgedPeptide FragmentsPlatelet Aggregation InhibitorsTime FactorsTreatment OutcomeConceptsNeuropsychological test batteryAlzheimer's diseaseDose-ranging phase 2 studyAlzheimer's Disease Cooperative Study-ActivitiesClass II trialsClinical efficacy outcomesCSF biomarker resultsScyllo-inositol concentrationsPhase 2 studyPrimary efficacy analysisHigh-dose groupDaily Living ScaleBrain ventricular volumeCoprimary endpointsEarly discontinuationEfficacy outcomesII trialADCS-ADLDose groupEfficacy analysisAcceptable safetyAβx-42Living ScaleOptimal doseTreatment groupsRevision of the criteria for Alzheimer's disease: A symposium
DeKosky ST, Carrillo MC, Phelps C, Knopman D, Petersen RC, Frank R, Schenk D, Masterman D, Siemers ER, Cedarbaum JM, Gold M, Miller DS, Morimoto BH, Khachaturian AS, Mohs RC. Revision of the criteria for Alzheimer's disease: A symposium. Alzheimer's & Dementia 2011, 7: e1-e12. PMID: 21322828, DOI: 10.1016/j.jalz.2010.12.007.Peer-Reviewed Original ResearchMeSH KeywordsAlzheimer DiseaseCognition DisordersCongresses as TopicHumansMagnetic Resonance ImagingNational Institute of Neurological Disorders and Stroke (U.S.)United StatesConceptsAlzheimer's diseaseClinical diagnosisRelated Disorders Association criteriaAlzheimer's Association Research RoundtableDefinitive clinical diagnosisCurrent diagnostic criteriaPotential diagnostic biomarkersPresymptomatic Alzheimer's diseaseCurrent standardMild cognitive impairmentClinical presentationAD pathologyClinicopathologic correlationAssociation criteriaDiagnostic criteriaMild stageCognitive impairmentDiagnostic biomarkersCommunicative DisordersResearch RoundtableDiseaseBetter ascertainmentGenetics of ADCurrent criteriaDiagnosis
1993
Administration of the new COMT inhibitor OR‐611 increases striatal uptake of fluorodopa
Guttman M, Léger G, Reches A, Evans A, Kuwabara H, Cedarbaum JM, Gjedde A. Administration of the new COMT inhibitor OR‐611 increases striatal uptake of fluorodopa. Movement Disorders 1993, 8: 298-304. PMID: 8341294, DOI: 10.1002/mds.870080308.Peer-Reviewed Original ResearchConceptsPositron emission tomographyNew COMT inhibitorL-DOPACOMT inhibitorsTreatment of patientsStriatal uptakeBrain uptakeBrain 6Cynomolgus monkeysParkinson's diseaseL-dopa analogEmission tomographyPromising agentSame animalsPET measurementsDiseaseMetabolismInhibitorsControl statePretreatmentPatientsFluorodopaAdjunctAdministrationUptake